COMT inhibitor

COMT inhibitor

Catechol-o-methyltransferase inhibitor Neurology A drug that enhances the effectiveness of levodopa by blocking COMT, an enzyme that metabolizes levodopa before it reaches the brain; ↑ levodopa bioavailability in the brain results in steady and continuous dopaminergic stimulation, and more consistent and effective symptom relief in Parkinson's disease
References in periodicals archive ?
COMT inhibitors: Entacapone is a peripherally acting COMT inhibitor, while tolcapone is able to cross the blood-brain barrier and acts both peripherally and in the CNS.
For example, the COMT inhibitor, tolcapone (Tasmar[R]), has been withdrawn from use in several countries (excluding the US) because it can increase liver problems by as much as 100%.
While the studies carried out in Europe have proved the effectiveness of this COMT inhibitor in L-dopa-induced hyperhomocysteinemia, no correlation has been demonstrated in studies conducted in the USA (2,22,24).
11) Tolcapone, a clinically approved COMT inhibitor for the treatment of PD, assists in managing problematic symptoms through maintenance of dopamine levels.
Many neurologists prefer prescribing levodopa and a COMT inhibitor in patients with severe disease, the guideline authors pointed out.
Tolcapone (Tasmar) is the first COMT inhibitor to be available and works both peripherally and centrally to allow a greater half-life of levodopa and dopamine.
In addition, new data points to the potential use of a COMT inhibitor that acts
CeNeS and Tripos Announce Advances in COMT inhibitor discovery programme
Additionally, patients may be receiving concomitant treatment with stable doses of a dopamine agonist, a COMT inhibitor, an anticholinergic and/or amantadine.
Tripos extended its COMT Inhibitor program, to treat Parkinson's disease, with CeNeS Pharmaceuticals plc.
With ND0612, LD concentration could be adjusted by controlling the infusion rate (programmed during day and night) and by adding oral LD/CD and a COMT inhibitor.
The co-promotion deal will also give both companies an increased profile within the field of neurology, a goal that Valeant has already taken great steps towards with its recent acquisition of the COMT inhibitor tolcapone (Tasmar(R)), which has received widespread support from movement disorders specialists and will be relaunched in the UK early next year.